Meta-analysis of α2-adrenergic agonists versus carbonic anhydrase inhibitors as adjunctive therapy

References

• The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Razeghinejad MR, Sawchyn AK, Katz LJ. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin Pharmacother 2010;11:959-68
   PubMed Web of Science ®Google Scholar
• Holló G, Bozkurt B, Irkec M. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother 2009;10:2015-24
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org [Last accessed 20 February 2012]
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
   PubMed Web of Science ®Google Scholar
• Simmons ST. Alphagan/Trusopt Study Group. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001;23:604-19
   PubMed Web of Science ®Google Scholar
• Hommer A, Kapik B, Shams N. Unoprostone Adjunctive Therapy Study Group. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. Br J Ophthalmol 2003;87:592-8
   PubMed Web of Science ®Google Scholar
• Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003;110:615-24
   PubMed Web of Science ®Google Scholar
• Carrasco Font C, Arias Puente A, et al. Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers. Arch Soc Esp Oftalmol 2004;79:163-8
   PubMedGoogle Scholar
• Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13:149-57
   PubMed Web of Science ®Google Scholar
• Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 2005;112:603-8
   PubMed Web of Science ®Google Scholar
• Reis R, Queiroz CF, Santos LC, et al. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther 2006;28:552-9
   PubMed Web of Science ®Google Scholar
• Feldman RM, Tanna AP, Gross RL, et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology 2007;114:1248-54
   PubMed Web of Science ®Google Scholar
• Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin 2008;24:1435-42
   PubMed Web of Science ®Google Scholar
• Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology 2009;116:1719-24
   PubMed Web of Science ®Google Scholar
• García-Feijoó J, Sáenz-Francés F, Martínez-de-la-Casa JM, et al. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol. Curr Med Res Opin 2010;26:1599-606
   PubMed Web of Science ®Google Scholar
• Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® Guidelines. Primary Open-Angle Glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2010. Available at: http://www.aao.org/ppp [Last accessed 20 February 2012]
   Google Scholar
• American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® Guidelines. Primary Open-Angle Glaucoma Suspect. San Francisco, CA: American Academy of Ophthalmology; 2010. Available at: http://www.aao.org/ppp [Last accessed 20 February 2012]
   Google Scholar
• Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology 2009;116:1243-9
   PubMed Web of Science ®Google Scholar
• Nixon DR, Yan DB, Chartrand JP, et al. Three-month, randomized, parallel-group comparison of brimonidine–timolol versus dorzolamide–timolol fixed-combination therapy. Curr Med Res Opin 2009;25:1645-53
   PubMed Web of Science ®Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine–purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119-26
   PubMed Web of Science ®Google Scholar
• Mundorf T, Williams R, Whitcup S, et al. A 3-month comparison of efficacy and safety of brimonidine–purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2003;19:37-44
   PubMed Web of Science ®Google Scholar
• Cantor LB, Safyan E, Liu CC, et al. Brimonidine–purite 0.1% versus brimonidine–purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr Med Res Opin 2008;24:2035-43
   PubMed Web of Science ®Google Scholar